文献速递脑血管病认知障碍与痴呆

ASCOT长期随访:卒中与痴呆发病及降压和他汀治疗的关系

Long-Term Incidence of Stroke and Dementia in ASCOT.
PubMed 文献 · Stroke · 2021-07-01

ASCOT研究纳入8580例英国高血压伴≥3个心血管危险因素患者,随机接受氨氯地平或阿替洛尔为基础降压方案5.5年,其中部分患者随机接受阿托伐他汀10 mg或安慰剂3.3年。随访至21年发现,氨氯地平方案降低卒中风险但未降低痴呆风险,阿托伐他汀对两者均无影响,血压变异性与痴呆和卒中风险升高相关。

要点

  • 氨氯地平为基础方案较阿替洛尔方案降低长期卒中风险(HR 0.82),但未降低痴呆风险。
  • 阿托伐他汀10 mg治疗3.3年对卒中(HR 0.92)和痴呆(HR 0.98)均无显著影响。
  • 血压变异性(平均血压标准差)每升高5 mm Hg与痴呆(HR 1.14)和卒中(HR 1.21)风险增加相关。

核心结论

  • 以氨氯地平为基础的降压方案较阿替洛尔为基础方案降低长期卒中发病率,但对痴呆无显著影响。
  • 阿托伐他汀对卒中或痴呆均无显著影响。
  • 较高的血压变异性与后期痴呆和卒中发病率升高相关。

研究设计与样本

  • ASCOT为随机对照试验,纳入高血压且≥3个心血管病危险因素患者,随机分配至氨氯地平或阿替洛尔为基础降压方案(目标血压<140/90 mm Hg)治疗5.5年。
  • 总胆固醇≤6.5 mmol/L者另行随机分配至阿托伐他汀10 mg或安慰剂治疗3.3年。
  • 英国参与者通过电子健康记录链接确定死亡和住院,共8580例英国参与者中7300例随访至随机化后21年。

主要发现

  • 阿托伐他汀3.3年对比安慰剂:卒中264例 vs 272例,调整后HR 0.92(95% CI 0.78–1.09),P=0.341;痴呆238例 vs 227例,调整后HR 0.98(95% CI 0.82–1.18),P=0.837。
  • 氨氯地平为基础方案对比阿替洛尔为基础方案5.5年:卒中443例 vs 522例,调整后HR 0.82(95% CI 0.72–0.93),P=0.003;痴呆450例 vs 465例,调整后HR 0.94(95% CI 0.82–1.07),P=0.334。
  • 平均总胆固醇与后期卒中或痴呆无显著关联。
  • 血压变异性(平均血压标准差)每5 mm Hg与痴呆风险升高相关(HR 1.14,95% CI 1.06–1.24,P<0.001),与卒中风险升高相关(HR 1.21,95% CI 1.12–1.32,P<0.001),均调整平均血压。

临床怎么用

  • 对于高血压伴多重心血管危险因素患者,选择以氨氯地平为基础的降压方案可能有助于降低长期卒中风险。
  • 阿托伐他汀10 mg治疗3.3年未显示对卒中或痴呆的长期预防作用,临床决策需结合其他适应证。
  • 关注血压变异性可能有助于识别痴呆和卒中高风险患者,但干预血压变异性能否改善预后尚不明确。

局限性

  • 痴呆和卒中通过电子健康记录编码列表和试验内 ascertainment 确定,可能存在漏诊或错分。
  • 阿托伐他汀治疗仅3.3年,随访至21年,长期效应可能被稀释。
  • 研究仅纳入英国参与者进行长期随访,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Management of stroke risk factors might reduce later dementia. In ASCOT (Anglo-Scandinavian Outcome Trial), we determined whether dementia or stroke were associated with different blood pressure (BP)–lowering regimens; atorvastatin or placebo; and mean BP, BP variability, and mean cholesterol levels. METHODS: Participants with hypertension and ≥3 cardiovascular disease risk factors were randomly allocated to amlodipine- or atenolol-based BP-lowering regimen targeting BP <140/90 mm Hg for 5.5 years. Participants with total cholesterol ≤6.5 mmol/L were also randomly allocated to atorvastatin 10 mg or placebo for 3.3 years. Mean and LDL (low-density lipoprotein) cholesterol, BP, and SD of BP were calculated from 6 months to end of trial. UK participants were linked to electronic health records to ascertain deaths and hospitalization in general and mental health hospitals. Dementia and stroke were ascertained by validated code lists and within-trial ascertainment. RESULTS: Of 8580 UK participants, 7300 were followed up to 21 years from randomization. Atorvastatin for 3.3 years had no measurable effect on stroke (264 versus 272; adjusted hazard ratio [HR], 0.92 [95% CI, 0.78–1.09]; P=0.341) or dementia (238 versus 227; adjusted HR, 0.98 [95% CI, 0.82–1.18]; P=0.837) compared with placebo. Mean total cholesterol was not associated with later stroke or dementia. An amlodipine-based compared with an atenolol-based regimen for 5.5 years reduced stroke (443 versus 522; adjusted HR, 0.82 [95% CI, 0.72–0.93]; P=0.003) but not dementia (450 versus 465; adjusted HR, 0.94 [95% CI, 0.82–1.07]; P=0.334) over follow-up. BP variability (SD mean BP) was associated with a higher risk of dementia (per 5 mm Hg HR, 1.14 [95% CI, 1.06–1.24]; P<0.001) and stroke (HR, 1.21 [95% CI, 1.12–1.32]; P<0.001) adjusted for mean BP. CONCLUSIONS: An amlodipine-based BP regimen reduced the long-term incidence of stroke compared with an atenolol-based regimen but had no measurable effect on dementia. Atorvastatin had no effect on either stroke or dementia. Higher BP variability was associated with a higher incidence of later dementia and stroke.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Whiteley WN, Gupta AK, Godec T, et al. Long-Term Incidence of Stroke and Dementia in ASCOT. Stroke. 2021. PMID: 34192893. doi:10.1161/STROKEAHA.120.033489

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。